Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Durvalumab + SNDX-6352|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 66||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov).|
|SNDX-6352||SNDX 6352|SNDX6352|UCB6352|Axatilimab||CSF1R Antibody 4||Axatilimab (SNDX-6352) is a humanized monoclonal antibody against colony-stimulating factor-1 receptor (CSF-1R), which may enhance anti-tumor immune response (SITC Meeting, Nov 2017, abstract P505).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT04301778||Phase II||Durvalumab + SNDX-6352||Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma||Not yet recruiting|
|NCT03238027||Phase I||SNDX-6352 Durvalumab + SNDX-6352||A Phase 1, Open-label, Dose Escalation Trial to Investigate SNDX-6352 in Patients With Solid Tumors||Active, not recruiting|